F or more than 5 decades, actuarial and population studies have identified the high prevalence of hypertension and its complications, and recent clinical trials have demonstrated the benefits of controlling this important medical problem. However, these studies have also raised a number of clinical and public health issues. These issues were reviewed and discussed at the National Heart, Lung, and Blood Institute (NHLBI) workshop on "Antihypertensive Drug Treatment: The Benefits, Costs, and Choices" held in Bethesda, Maryland on June [11][12]1987. This supplement to Hypertension contains the Proceedings from that workshop.
